High-Sensitivity C-Reactive Protein: A Useful Marker for Cardiovascular Disease Risk Prediction and the Metabolic Syndrome

Rifai, Nader

doi:10.1373/clinchem.2004.044990

Cited by 28 publications

(16 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,18 High-sensitivity C-reactive protein (hs-CRP) which has important clinical and prognostic implications in cardiovascular disease; however, has not been well studied in NAFLD. 25 High-sensitivity C-reactive protein (hs-CRP) assay is a marker of inflammation and is a recommended for use as a part of coronary risk assessment in adults with intermediate cardiovascular risk. In our study, the hs-CRP levels were significantly higher in the NAFLD group compared to cases without NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α

Ajmal

Yaccha²,

Malik

et al. 2014

Indian Heart Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α

Ajmal

Yaccha²,

Malik

et al. 2014

Indian Heart Journal

View full text Add to dashboard Cite

show abstract

“…High-sensitivity C-reactive protein (hs-CRP), a representative acute phase reactant, is a marker of atherosclerosis and endothelial cell dysfunction. Several studies have demonstrated that hs-CRP is a strong predictor and prognostic factor of future cardiovascular disease and is associated with the components of MetS [8,9]. In contrast, adiponectin is a plasma adipocytokine that is normally present at levels of up to 5 to 10 µg/mL on average and is known to prevent atherosclerotic vascular changes and impairments of glucose and lipid metabolism.…”

Section: Introductionmentioning

confidence: 99%

Measurement of antioxidant capacity using the biological antioxidant potential test and its role as a predictive marker of metabolic syndrome

Kim

Baik

Yoon

et al. 2014

Korean J Intern Med

View full text Add to dashboard Cite

Background/AimsOxidative stress increases the risk of cardiovascular complications of metabolic syndrome (MetS). This study was conducted to examine the difference in antioxidant capacity according to the presence of MetS, and to characterize the association between antioxidant capacity and MetS-related factors.MethodsWe used the biological antioxidant potential (BAP) test to estimate antioxidant capacity. The BAP test has recently been used as an indicator of antioxidant capacity. We measured BAP levels in 45 patients with MetS (mean age, 44.6 ± 1.1 years) and 47 age- and sex-matched controls (mean age, 42.7 ± 1.1 years). To evaluate the association between antioxidant capacity and MetS, adiponectin, high-sensitivity C-reactive protein (hs-CRP), interleukin-6, tumor necrosis factor-α, and homeostatic model assessment for insulin resistance (HOMA-IR), linear regression and logistic analyses were performed.ResultsThe mean BAP of the MetS group (1,937.3 ± 36.5 µmol/L) was significantly lower than that of the non-MetS group (2,101.7 ± 29.5 µmol/L). Also, the mean BAP was low in persons having low high density lipoprotein and high triglyceride. Reduced antioxidant capacity was significantly associated with adiponectin, HOMA-IR and hs-CRP after adjusting for age and sex. The odds ratios for MetS with BAP, log adiponectin, log HOMA-IR, and log hs-CRP were 0.63 (95% confidence interval [CI], 0.49 to 0.82), 0.22 (0.10 to 0.51), 14.24 (4.35 to 46.58), and 1.93 (1.36 to 2.75), respectively.ConclusionsPersons with MetS showed reduced antioxidant capacity. We identified relationships between antioxidant capacity measured by BAP test and MetS, as well as MetS-related factors, such as insulin resistance, hs-CRP, and adiponectin.

show abstract

“…Several inflammatory processes, mainly associated with tumor necrosis factor α, have been associated with NAFLD [11,12], however, this inflammatory pathway is shared by other diseases with a similar inflammatory background as cardiovascular disease [13][14][15]. Many inflammatory markers have been described in such diseases; in particular, ultrasensitivity C-reactive protein (uCRP) has important clinical and prognostic implications in cardiovascular disease, however, this marker had not been analyzed in NAFLD [16][17][18]. The aim of this study was to determine the relationship between uCRP and NAFLD in middle-aged asymptomatic subjects independently of other metabolic disturbances associated with metabolic syndrome and cardiovascular risk.…”

Section: Introductionmentioning

confidence: 99%

Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk

et al. 2007

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is associated with several metabolic disturbances involving inflammation. Ultrasensitive C-reactive protein (uCRP), a marker of coronary heart disease and other chronic diseases, has not been investigated in NAFLD. We tested the relationship between uCRP and NAFLD in middle-aged asymptomatic subjects, independently of other metabolic disturbances associated with metabolic syndrome and cardiovascular risk. We compared 310 subjects with steatosis visible on ultrasound (cases) with 630 and without (controls). Body mass index (BMI), blood pressure and serum levels of uCRP, glucose, lipids, and lipoproteins were measured in all subjects. Differences between groups and the impact of serum uCRP levels were tested by univariate and multivariate logistic regression analysis. Cases were statistically different from controls in the frequency of metabolic syndrome (66.4% vs. 26.7%; P < 0.001). Cases were significantly older (P < 0.001), and had significantly higher values for BMI, glucose, total cholesterol and triglycerides (P < 0.001), and mean uCRP concentrations (4.5 vs. 2.79 mg/L; P < 0.001). By univariate analysis, variables significantly associated with cases were glucose (OR, 4.09; 95% CI, 2.98-5.61), BMI (OR 5.54; 95% CI, 4.09-7.49), and uCRP (OR 7.06; 95% CI, 4.51-11.02). By multivariate analysis, uCRP levels were associated with hepatic steatosis (OR 5.83; 95% CI, 3.07-11.06). Cardiovascular risk was also higher in subjects with NAFLD (4.7 vs. 2.8). Subjects with hepatic steatosis showed an increased concentration of uCRP independently of other metabolic disturbances; this suggests an increased risk of cardiovascular diseases and could be used as a marker of chronic inflammation.

show abstract

High-Sensitivity C-Reactive Protein: A Useful Marker for Cardiovascular Disease Risk Prediction and the Metabolic Syndrome

Cited by 28 publications

References 8 publications

Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α

Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α

Measurement of antioxidant capacity using the biological antioxidant potential test and its role as a predictive marker of metabolic syndrome

Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk

Contact Info

Product

Resources

About